Track record · closed signal

Hims & Hers Health, Inc. (HIMS) — closed signal from December 16, 2025

Partial Published before the outcome was known, scored automatically when the window closed on March 16, 2026 — -32% at the close.

Predicted vs. what happened

HIMS price · publication thesis → realized outcomesplit-adjusted

$34.50 – $36.80Entry zone — fair-value band

$36.59Published — price the day we called it

$43.18Target — the price the thesis aimed for

$37.61Peak — highest point inside the window, not a realized return

$24.88Window close — end-of-window price, context only

What happened

Partial

Reached 16% of the predicted growth at its peak, without hitting the target.

At window close

-32%

realized, from the publication price to the last close inside the window

Peak gain

+2.8%

peak, from the publication price — not a realized return

S&P 500, same window

-1.2%

SPY over the identical days, dividend-adjusted

Window close

$24.88

last close inside the window, ended March 16, 2026

Peak price

$37.61

peak on December 17, 2025 — not a realized return

Days to target

—

The thesis — published December 16, 2025

Predicted growth

+18%

over the measurement window

Target price

$43.18

the price the thesis aimed for

Entry zone

$34.50 – $36.80

the fair-value band we waited for

Price at publication

$36.59

published December 16, 2025

Confidence

62%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

HIMS is a risky stock that often moves a lot in a short time. Its new weight-management program coming to the UK on Dec 12 gives a clear reason for more sales and investor interest. The stock has fallen a lot already, so it can bounce higher quickly but those bounces often fail. If you buy, use small buys near the stated price zone and be ready to sell fast if the stock doesn't keep moving up.

Primary drivers

UK product launch on Dec 12 could boost sales and attention
Investor focus on obesity treatments keeps interest high
A heavy recent sell-off can lead to quick rebounds
Strong competition and mood-driven pricing add downside risk

How it played out

HIMS: the target was not reached

Lyra published HIMS at $36.59 on Dec. 16, 2025, with an expected gain of 18% and a target of $43.18. The thesis pointed to the UK weight-management launch on Dec. 12, continued investor interest in obesity treatments, a possible rebound after a heavy sell-off, and downside risk from competition and mood-driven pricing.

Inside the window, HIMS peaked at $37.61 on Dec. 17, 2025. That was a 2.8% gain, but it stayed below the $43.18 target. It never got there. By Mar. 16, 2026, the stock ended at $24.88. The thesis missed.

What happened during the window

On Feb. 19, 2026, Hims & Hers announced an agreement to acquire Eucalyptus, an Australian digital health provider. The report said the deal was valued at $1.15 billion and was expected to close in mid-2026.

Hims & Hers is spending more than $1 billion in a push to expand globally

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HIMS signals